Novo Nordisk Plunges 10% — The “Magic Pill” Myth Collapses
Novo Nordisk experienced a 10% stock plunge following the failure of its Alzheimer's trial. The episode analyzes the failed 'Evoke' data, Eli Lilly's market cap achievement, and Novo Nordisk's challenging position in the obesity drug market.